Evoke Pharma Appoints Matthew J. D'Onofrio as CEO Amidst Senior Leadership Shift

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. EVOK, a company dedicated to the creation of therapeutics for gastrointestinal diseases, has initiated a significant change in its executive ranks by elevating Matthew J. D'Onofrio to the role of Chief Executive Officer. The announcement marks a pivotal step for the pharmaceutical company as it continues to place a strategic emphasis on the commercialization and development of treatments such as their GIMOTI® (metoclopramide) nasal spray.

Leading the Way in GI Therapeutics

The leadership transition underscores Evoke Pharma's commitment to spearheading innovative treatments within the GI sector. With a base in Solana Beach, California, Evoke Pharma has carved a niche primarily within gastroenterological medicine, concentrating on drugs that address prevalent and impactful GI disorders. The promotion of Matthew J. D'Onofrio heralds a new chapter for the company as it fortifies its position within the specialty pharmaceutical market.

A Strategic Evolution

The appointment of D'Onofrio reflects Evoke Pharma's strategic alignment with evolving market demands and its intent to stay ahead in the competitive landscape of GI treatment solutions. By driving forward programs like their flagship GIMOTI® nasal spray, which offers an innovative approach to treating symptoms associated with acute and recurrent diabetic gastroparesis, Evoke Pharma reinforces its dedication to enhancing patient care through advanced therapeutics.

Evoke, Leadership, GIMOTI